Polycystic Kidney Disease Drugs Market to Grow at a CAGR of 5.90% During 2026-2035, Aided by the Rising Prevalence of Polycystic Kidney Disease Across the 8 Major Markets

Polycystic Kidney Disease Drugs Market Overview

Polycystic kidney disease (PKD) refers to a genetic disorder that is characterized by the formation of fluid-filled sacs (cysts) in the kidneys. The disease can result in serious complications, including high blood pressure and kidney failure. The increasing prevalence of polycystic kidney disease, especially the autosomal dominant form, is expected to fuel the market growth. The rising advancements in drug development and the growth in new drug approvals are poised to augment the market demand. Additionally, the growing focus on symptom management and the rise in clinical trials are likely to influence the polycystic kidney disease drugs market landscape.

Key Findings

• Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic cause of kidney failure, affecting roughly 1 in 400 to 1,000 people and around 500,000 individuals in the United States, with about half of patients progressing to end-stage renal disease by age 60.
• Tolvaptan remains the only approved disease-modifying therapy for ADPKD, leaving substantial unmet need for treatments with better efficacy and tolerability and creating a clear opening for next-generation drugs.
• The pipeline is expanding with novel mechanisms, including microRNA-targeting oligonucleotides and improved vasopressin receptor antagonists, aimed at slowing cyst growth and kidney enlargement while avoiding the limitations of current therapy.

Polycystic Kidney Disease Drugs Market Demand Drivers

Autosomal dominant polycystic kidney disease constitutes the more prevalent form of polycystic kidney disease, affecting 1 in 400 to 1000 individuals. On the other hand, autosomal recessive polycystic kidney is reported to have an estimated prevalence of 1 in 20,000 to 40,000 people. The increasing prevalence of polycystic kidney disease is one of the key factors propelling the demand for effective medications that can slow disease progression and manage symptoms.

Polycystic Kidney Disease Drugs Market Segmentation Analysis

The Disease Type Segment is Anticipated to Witness Significant Growth in the Forecast Period

Based on the disease type, the market segmentation includes autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD), among other rare forms. Autosomal dominant polycystic kidney disease is an inherited genetic disorder that causes the development of numerous cysts in the kidneys and results in progressive kidney damage over time. The drug tolvaptan shows high efficacy in slowing the progression of kidney function decline in autosomal dominant polycystic kidney disease and thus is commonly used for the treatment of the condition. The market is witnessing a growing demand for medications that help in symptom management of ADPKD such as hypertension, pain, and kidney infections, which is likely to contribute to the market expansion in the coming years.

The market report also offers insights based on the mechanism of action, route of administration, end-user, and region.

Polycystic Kidney Disease Drugs Market: Competitive Landscape

• In April 2025, Novartis agreed to acquire Regulus Therapeutics for up to around USD 1.7 billion, comprising USD 0.8 billion upfront (USD 7.00 per share) and a contingent value right of up to a further USD 0.9 billion on a regulatory milestone, to gain farabursen (RGLS8429), a first-in-class next-generation oligonucleotide targeting miR-17 for ADPKD, with the deal expected to close in the second half of 2025.
• In March 2025, Regulus completed the Phase 1b multiple-ascending dose trial of farabursen, reporting encouraging safety and effects on urinary polycystin and kidney volume growth, and reached FDA alignment on a single Phase 3 pivotal trial designed for potential accelerated approval.
• Other players include AbbVie, Amgen, F. Hoffmann-La Roche, Otsuka Holdings Co. Ltd., Palladio Biosciences Inc., Galapagos, Johnson & Johnson, Merck & Co, XORTX Therapeutics Inc., Sanofi, Teva, Bayer, and Apotex, spanning branded and generic kidney and supportive therapies.

Polycystic Kidney Disease Drugs Market Analysis by Region

The United States is Projected to Lead the Market Share

The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States is projected to dominate the market for polycystic kidney disease drugs due to the high prevalence of autosomal dominant polycystic kidney disease and the presence of a well-established healthcare system. The robust regulatory framework and the growing demand for innovative therapies also support the market growth. Moreover, the rising R&D investment in rare and genetic diseases and increasing healthcare spending are anticipated to boost the market expansion in the country.

Key Offerings of the Report

• The Expert Market Research report gives an overview of the market for polycystic kidney disease drugs for the time span of (2019-2025) and (2026-2035).
• The report also offers historical (2019-2025) and forecast (2026-2035) market information for the disease type, mechanism of action, route of administration, end user, and region of the market.
• The report analyses the market dynamics, covering the key demand and price indicators in the market, along with providing an assessment of the SWOT and Porter’s Five Forces models.

About Us

Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which is constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.

EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.

Contact Us

Expert Market Research
Website: www.expertmarketresearch.com 
Email: sales@expertmarketresearch.com
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790